Diseases of the Digestive System - Liver, Phase III

A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)

Volunteers
Health Professionals

What is the purpose of this trial?

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3.

Trial with
Inventiva Pharma
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Szymanski

beth.szymanski@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Joseph Lim, MD
Professor of Medicine; Director, Clinical Hepatology, Digestive Diseases; Vice-Chief of Hepatology, Section of Digestive Diseases, Digestive Diseases; Director, Yale Viral Hepatitis Program

Sub-Investigator

Simona Jakab, MD

Last Updated
11/05/2023
Study HIC
#2000030905